We now see the next wave of potential cancer therapies on the horizon, propelled by significant advancements in immunology, as well as an increased understanding of tumor-driven mechanisms of immune evasion.
As is the case with many big biopharma execs, Biogen's R&D head Douglas Williams is leaving to launch an as-yet-unnamed new cancer diagnostics or therapeutics startup, Biogen says.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Ohio State University and the University of Michigan have decided put some rivalry aside and create a company, Sirona Therapeutics, that partnered with Ohio-based Venture Therapeutics. The partnership will form a new company to develop and commercialize new technology to treat precancerous oral lesions. The Ohio State Innovation Foundation and Drug Development Institute and […]